FASEB Conference: Genome Engineering: Research and...
CMN Briefs
May. 7, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Cimeio Therapeutics
Company Type: Therapeutics
Main focus: Gene editing and immunotherapy to transform haematopoietic stem cell transplantation
Company stage: Pre-clinical
Diseases: Genetic diseases, haematologic malignancies, and severe autoimmune disorders
Genome-editing tool: Prime editing
Funding stage: Series B
Location: Basel, Switzerland
Website: https://www.cimeio.com
Pipeline:
Partners: Prime Medicine
Cimeio is an applied gene-editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ (SCIP), which has the potential to transform haematopoietic stem cell (HSC) transplantation. The company's technology platform is based upon the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, haematologic malignancies, and severe autoimmune disorders.
